Medivir AB (MVIRb.F) Announces That Simeprevir Data Will be Presented at the Upcoming American Association for Study of Liver Diseases Meeting  
10/1/2013 9:47:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Stockholm, Sweden — Medivir AB (OMX: MVIR) announced that data will be presented on the investigational protease inhibitor simeprevir for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place November 1 to 5 in Washington, D.C.

Help employers find you! Check out all the jobs and post your resume.